{"podcast":{"title":"Rand Radio","slug":"rand-radio-7193419","podcast_index_feed_id":7193419,"rss_url":"https://api.substack.com/feed/podcast/1627785.rss","website_url":"https://www.randpaulreview.com/podcast","image_url":"https://substackcdn.com/feed/podcast/1627785/d0bb836829be9d07d03f6c0a17f5e09d.jpg","author":"Rand Paul Review","episode_count":84,"summary":"For liberty to expand, government must shrink. For the economy to grow, government must get out of the way. -- Rand Paul. [Unofficial Rand Paul fan-stack.]","last_synced_at":"2026-07-22T00:20:12.959108+00:00","page_url":"https://stenobird.com/podcast/rand-radio-7193419"},"episode":{"title":"Allowing Biosimilars Will Change the Game","slug":"allowing-biosimilars-will-change-the-game","published_at":"2026-01-10T16:51:00+00:00","page_url":"https://stenobird.com/podcast/rand-radio-7193419/allowing-biosimilars-will-change-the-game","show_page_url":"https://stenobird.com/podcast/rand-radio-7193419","url":"https://www.randpaulreview.com/p/allowing-biosimilars-will-change","audio_url":"https://api.substack.com/feed/podcast/181701943/6389e1cc4a6d075fd4077771f803623f.mp3","summary":"Americans spend more on healthcare than any other nation. We also have one of the worst returns on healthcare investment in the world. Why is that? Rand Paul knows why: there’s too much bureaucracy and regulation stifling competition. Our flawed approach to healthcare leads to higher drug prices, extended illness, and shorter lives. Paul Wants to Fast-track Biosimilars Paul, an accomplished doctor, insists today’s science shows biosimilars are the equivalent of highly effective drugs. The difference between biosimilars and brand name medications? Biosimilars, sometimes referred to as “generics”, are more economical for patients. Moreover, biosimilars don’t require arguably pointless clinical studies. The Kentucky Senator authored a bill designed to persuade the Food and Drug Administration to adhere to evidence proving the merit of biosimilars. The FDA took Paul’s advice, implementing reform to reduce costs without sacrificing medication quality. Affordable Drugs Without the Red Tape Thanks to Paul’s legislation , the path is paved to fast-track biosimilars. What’s the plan? Paul’s bill streamlines the bogged down process for biosimilar approval. The idea is to eliminate repetitive requirements for clinical studies that waste time, effort, and money. The bill, dubbed Expedited Access to Biosimilars Act, hikes competition, boosts access to treatments that save lives, and decreases medication prices. “For years, biopharmaceutical researchers have argued that new and advanced methods of determining biosimilar clinical equivalence in early development have eliminated the need for late-stage human studies. When a biosimilar proves it is safe, effective, and similar to the brand name product in the early stages of its analytical and safety assessment, there’s no scientific j…","meta_description":"Americans spend more on healthcare than any other nation. We also have one of the worst returns on healthcare investment in the world. Why is that? Rand P…","key_points":[],"chapters":[],"topics":[],"duration_seconds":53,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/rand-radio-7193419/episodes/allowing-biosimilars-will-change-the-game/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/rand-radio-7193419/allowing-biosimilars-will-change-the-game.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}